Chemo-Immuno cocktail shows promise in early cancer trial
NCT ID NCT05276284
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastatic cancer and aimed to find the safest dose and check for any tumor shrinkage. The trial is now complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (immunotherapy) combined with 6-mercaptopurine and 6-thioguanine (chemotherapy drugs)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, small trial (18 participants) focused on safety and dosing. The combination may cause significant side effects, and it is unknown if it will effectively shrink tumors or extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Copenhagen, Rigshospitalet
Copenhagen, 2100, Denmark